Feb

2012

Topica Pharmaceuticals, Inc.: Series B $27M

Posted in I - Series B, Q - 4Q11, R - WEST, X - Antifungal, X - Antiinfective, XX - CA

Topica Pharmaceuticals (Palo Alto, CA) a clinical-stage pharmaceutical company focused on treatments for onychomycosis, closed a $27M Series B financing. Participants include Third Rock Ventures, Prospect Venture Partners and Yasuda Enterprise Development Corporation.

Feb

2012

Allena Pharmaceuticals, Inc.: Series A $15M

Posted in I - Series A, Q - 4Q11, R - NORTH EAST, X - Renal, X - Urology, XX - MA

Allena Pharmaceuticals (Newton, MA) a preclinical-stage biopharmaceutical company focused on nephrologic and urologic conditions, closed a $15M Series A financing. Participants include Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures.

Feb

2012

Ember Therapeutics, Inc.: Series A $34.1M

Posted in I - Series A, Q - 4Q11, R - NORTH EAST, X - Diabetes, X - Metabolism, X - Obesity, X - Therapeutic Platform, XX - MA

Ember Therapeutics (Boston, MA) a preclinical-stage pharmaceutical company focused on diabetes, obesity and metabolic diseases closed a $34.1M Series A financing. Participants include Third Rock Ventures.

Jan

2012

Agios Pharmaceuticals, Inc.: Series C $78M

Posted in I - Series C, Q - 4Q11, R - NORTH EAST, X - Metabolism, X - Oncology, XX - MA

Agios Pharmaceuticals (Cambridge, MA) a clinical-stage biopharmaceutical company focused on cancer metabolism, closed a $78M Series C financing. Participants have included Celgene, ARCH Venture Partners, Flagship Ventures and Third Rock Ventures.

Jan

2012

Zafgen, Inc.: Series C $33M

Posted in I - Series C, Q - 3Q11, R - NORTH EAST, X - Obesity, XX - MA

Zafgen (Cambridge, MA) a clinical-stage biopharmaceutical company focused on small molecule therapeutics for the treatment of obesity, closed a $33M Series C financing. Participants include Atlas Venture and Third Rock Ventures.
Thanx for your patience as we catch-up.

Aug

2011

Constellation Pharmaceuticals, Inc.: Series B $15M

Posted in I - Series B, Q - 2Q11, R - NORTH EAST, X - Epigenetics, X - Immunology, X - Inflammation, X - Oncology, XX - MA

Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on small molecule therapeutics against chromatin-based targets to treat cancer and inflammatory disorders, closed a $15M Series B financing bringing the total round to $37M. Participants include S.R. One, Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock.
The 2Q11 OnBioVC Trend Analysis will be [...]

Aug

2011

Lotus Tissue Repair, Inc.: Series A $26M

Posted in I - Series A, Q - 2Q11, R - NORTH EAST, X - Dermatology, XX - MA

Lotus Tissue Repair (Cambridge, MA) a development-stage biopharmaceutical company focused on dystrophic epidermolysis bullosa and other dermatologic conditions, closed a $26M Series A financing. Participants include Third Rock Ventures.

Jul

2011

Taris Biomedical, Inc.: Series B $18.3M

Posted in I - Series B, Q - 2Q11, R - NORTH EAST, X - Incontinence, X - Inflammation, X - Oncology, XX - MA

Taris Biomedical (Lexington, MA) a clinical-stage specialty pharmaceutical company focused on bladder diseases in pain, inflammation, oncology and incontinence, closed a $18.3M Series B financing. Participants include Third Rock Ventures, Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners.

Jul

2011

Blueprint Medicines, Inc.: Series A $40M

Posted in I - Series A, Q - 2Q11, R - NORTH EAST, X - Oncology, XX - MA

Blueprint Medicines (Cambridge, MA) a development-stage biopharmaceutical company focused on personalized cancer therapies, closed a $40M Series A financing. Participants include Third Rock Ventures.

Jul

2011

BlueBird Bio, Inc.: Series C $30M

Posted in I - Series C, Q - 2Q11, R - NORTH EAST, X - Gene Therapy, X - Stem Cell, XX - MA

BlueBird Bio (Cambridge, MA) a clinical-stage developer of innovative stem cell-based gene therapies for severe genetic disorders, closed a $30M Series C financing. Participants include Arch Venture Partners, Third Rock Ventures, TVM Capital, Forbion Capital Partners and Easton Capital Investment Group.

Apr

2011

PanOptica, Inc.: Series A $30M

Posted in I - Series A, Q - 1Q11, R - NORTH EAST, X - Opthalmology, XX - NJ

PanOptica (Mount Arlington, NJ) a development-stage biopharma company focused on in licensing IND-stage ophthalmology assets, closed a $30M Series A financing. Participants include SV Life Sciences and Third Rock Ventures.

Jan

2011

Kala Pharmaceuticals, Inc.: Series B $3M

Posted in I - Series B, Q - 4Q10, R - NORTH EAST, XX - MA

Kala Pharmaceuticals (Waltham, MA) an early-stage stealth-mode biopharma closed a $3M Series B financing. Participants may include Lux Capital, Polaris Venture Partners and Third Rock Ventures.

Nov

2010

NinePoint Medical, Inc.: Series A $33M

Posted in I - Series A, Q - 4Q10, R - NORTH EAST, X - Device (Diagnostic), X - Oncology, XX - MA

Nine Point Medical (Cambridge, MA) a development-stage medical device and diagnostic company focused on optical technologies for real-time in vivo pathology decision making, closed a $33M Series A financing. Participants include Third Rock Ventures and Prospect Venture Partners.
_________________________________________________________________________
OnBioVC is exceedingly thankful for among many things the steadfast support for all of our readers and subscribers. [...]

« Previous Entries

to top of page...